New study seeks to uncover hidden cancer risks in families with rare gene mutation

NCT ID NCT05126290

Recruiting now Knowledge-focused Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at people with a specific genetic change in the CTNNA1 gene, which may increase the risk of stomach and breast cancers. Researchers will collect family health histories from 100 participants to better understand these risks. The goal is to improve cancer screening and prevention for families carrying this gene variant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could clarify the cancer risks associated with CTNNA1 mutations, helping guide screening and prevention for affected families.
What could go wrong: This is an observational study, not a treatment trial. It may not find clear links due to small sample size or genetic complexity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CANCER GENE MUTATION GASTRIC CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Abramson Cancer Center of the University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.